Comprehensive Analysis of the Shingrix (Zostavax) Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the shingrix (zostavax) market grown in recent years?
In recent times, the market size for Shingrix (Zostavax) has encountered a HCAGR of XX. It’s projected to expand from a value of $XX million in 2024 to $XX million in 2025, experiencing a Compound Annual Growth Rate (CAGR) of XX%. The surge in market growth seen in the historical period is a result of several factors – broader acceptance of the vaccine, the growing necessity of educational campaigns, an escalated emphasis on preemptive healthcare, an increase in efforts towards patient education and advocacy, and the enhancement of insurance coverage for immunization.
How is the shingrix (zostavax) market size expected to evolve during the forecast period?
In the coming years, an XX (FCAGR) increase is anticipated in the market size for shingrix (zostavax). By 2029, the market is predicted to expand to $XX million, with an XX% compound annual growth rate (CAGR). This surge over the forecast period can be credited to the growing elderly population, a rise in herpes zoster cases, an increase in chickenpox instances, a higher disease prevalence, and more education about shingles and its serious health implications. Major trend shifts during this forecast period consist of innovative recombinant vaccines, advancements in the field of vaccine development, a preference for disease prevention rather than treatment, research and development of vaccines powered by AI, and the identification of advanced biomarkers for shingles susceptibility.
Get your shingrix (zostavax) market report here!
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report
Which key drivers are propelling the shingrix (zostavax) market’s growth?
The escalation in embracing vaccinations is anticipated to enhance the expansion of the Shingrix (Zostavax) market. The act of administering a vaccine to stimulate the immune system of the body to identify and combat particular pathogens is referred to as vaccination. The boosted adoption of vaccination is credited to heightened awareness of its efficacy in illness prevention, diminishing disease load, and the formulation of safe and obtainable vaccines. Public health drives, enhanced medical infrastructure, and international vaccination initiatives also feed into its widespread assimilation. The Shingrix (Zostavax) is conducive for vaccination by offering effectual defense against shingles and their complications. It proves exceptionally beneficial for adults over the age of 50, reducing the possibility of shingles recurrence and post-herpetic neuralgia significantly. For example, a study by the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical journal, in May 2024 revealed a 46% increase in shingles vaccinations covered by Medicare Part D in the year following the IRA policy’s enforcement in January 2023. Additionally, in 2022, the Australian Government Department of Health and Aged Care, an Australian government agency, ensured free availability of Covid-19 vaccines to all Australians. Over 34 million initial vaccinations and boosters had been administered by mid-2022, with general practices playing a considerable role in the rollout, specifically in rural regions. Hence, the surge in vaccination adoption is propelling the growth of the Shingrix (Zostavax) market.
What are the market segments in the shingrix (zostavax) industry?
The shingrix (zostavax) market covered in this report is segmented –
1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp
Which leading companies are shaping the growth of the shingrix (zostavax) market?
Major companies operating in the shingrix (zostavax) market are GSK plc
What key trends are currently impacting the shingrix (zostavax) market’s development?
In the shingrix (zostavax) market, an emerging trend involves the creation of groundbreaking products such as non-live recombinant subunit adjuvanted vaccines which are design to improve the effectiveness of vaccines and tackle age-associated immune decline in at-risk groups. These non-live vaccines combine specific protein constituents of a pathogen with an adjuvant to amplify the immune response. As an example, in September 2024, the shingles vaccine Shingrix was introduced by UK biopharma company GSK plc. The Recombinant Zoster Vaccine (RZV), a non-live vaccine, has shown up to 97% efficacy in preventing shingles and post-herpetic neuralgia and is aimed at adults aged over 50 and the immunocompromised aged over 18. The vaccine is delivered intramuscularly in a series of two doses. As per the ZOE-50 study, RZV demonstrated up to 97% potency in adults aged 50 and above over a three year period, with new data suggesting above 80% efficacy can be maintained 6–10 years after the initial vaccination.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20264
Which geographic areas are influencing the growth of the shingrix (zostavax) market?
North America was the largest region in the shingrix (zostavax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Human Immunodeficiency Virus (HIV) Diagnosis Global Market Report 2025
Immunoglobulin E (IgE) Allergy Blood Tests Global Market Report 2025
Immunomodulator Global Market Report 2025
https://thebusinessresearchcompany.com/report/immunomodulator-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
